In the scope of this project, the EORTC Quality of Life Group aims to provide concrete guidance on interpreting PRO data assessed with its own measures.
Principal Investigator
Monika Sztankay
University Clinic of Psychiatry II
Medical University of Innsbruck
Project Coordinator
Daniela Krepper
Medical University of Innsbruck
Collaborators
Madeline Pe & Dagmara Kulis, EORTC Quality of Life Department, Brussels, Belgium
Zebedee Jammbe Musoro & Corneel Coens, EORTC HQ, Brussels, Belgium
Johannes Giesinger & Lisa Wintner, Medical University of Innsbruck, Innsbruck, Austria
Heike Schmidt, Institute of Health and Nursing Science; University Hospital Halle (Saale), Germany
Razvan Mircea Galalae,EBG MedAustron, Germany
Katarzyna Pogoda, Marie-Sklodowska-Curie Institute, Warsaw, Poland
Kelly de Ligt, Netherlands Cancer Institute, Amsterdam, The Netherlands
Vesna Bjelic-Radisic, Medizinische Universität, Graz, Austria
Advisory Board
Madeleine T. King, University of Sydney, Sydney, Australia
Teresa Young, East & North Hertfordshire NHS Trust, UK
Mogens Groenvold, The Palliative Care Research Unit, Department of Geriatrics and Palliative Medicine GP, Bispebjerg and Frederiksberg Hospital, University of Copenhagen & Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Galina Velikova, St James’s Institute of Oncology, Leeds Teaching Hospitals & Faculty of Medicine and Health, School of Medicine, University of Leeds, Leeds, UK
Anne Brédart, Institut Curie, Supportive Care Department, Psycho-Oncology Unit, Paris, France
Bernhard Holzner, Medical University of Innsbruck, Innsbruck, Austria
Eva Gamper, Medical University of Innsbruck, Austria
Lonneke van de Poll-Franse, Netherlands Cancer Institute, Amsterdam, The Netherlands
Kristin Bjordal, Department of Research Support Services, Oslo University Hospital & Institute for Clinical Medicine, University of Oslo, Oslo, Norway
John Ramage, Hampshire Hospitals NHS Trust, Kings College Hospital ENETS centre of Excellence, Basingstoke, UK
Juan Ignacio Arraras, Oncology Departments, Complejo Hospitalario de Navarra, Pamplona, Spain
Charalampia Kyriakou, University College London Hospital, London, UK
Linda Dirven, Leiden University Medical Centre, The Netherlands
Jacobien Kieffer, Netherlands Cancer Institute, Amsterdam, The Netherlands
Jolie Ringash, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Canada
Tito Mendoza, The University of Texas, MD Anderson Cancer Centre, Texas, USA
Amylou Dueck, Mayo Clinic, Arizona, USA
Project summary
The assessment of PRO data in oncological practice and research has proved to be beneficial for patient outcomes. By offering guidance on interpretation, the EORTC QLG aims to support the use of PRO data assessed with its measures. To meet the need for practical guidelines on how to differentiate and use the various ways of interpreting EORTC PRO data, we aim to develop a guideline including best practice recommendations on interpreting PROs assessed with EORTC PRO measures for scientific as well as clinical use. The recommendations in the guideline will be based on existing evidence and consensus between PRO experts in the field, including buy-in from relevant stakeholders (i.e. patient representatives, clinicians, researcher, pharma representatives).
Project status
The study protocol has been finalised and we have started collating the evidence for the guideline scope (by means of systematic literature review, expert call and stakeholder assessment).